Using Candida antigen and a bivalent HPV vaccine to clear multiple common warts
Official title: Candida Antigen and Bivalent HPV Vaccine in the Treatment of Multiple Warts: Monotherapy Versus Combined Therapy
Run by Zagazig University · NCT05291845 · Data updated 2026-11-12
This study will test whether injections of Candida antigen, a bivalent HPV vaccine, or both can clear multiple common warts in people with persistent or widespread warts.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Ages | 9 Years and up |
| Sex | All |
| Enrollment | 162 (estimated) |
| Sponsor | Zagazig University Government |
| Locations | 1 site (Zagazig, Al Sharqia) |
| Status | Recruiting |
| Started | April 3, 2022 |
| Main results expected | October 3, 2025 |
| Study ends | December 6, 2025 |
| Registry record updated | June 12, 2025 |
| Trial ID | NCT05291845 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
People with multiple common warts, including recalcitrant or widespread lesions, who can attend biweekly clinic visits and are not pregnant or allergic to the study agents would be suitable candidates.
✕Probably not a fit
Pregnant individuals and anyone with a known hypersensitivity to Candida antigen or the bivalent HPV vaccine are excluded and would not be expected to benefit, and patients with single isolated lesions or non-HPV skin conditions may derive little advantage.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This Phase 2 interventional study will enroll 162 participants with multiple common warts and randomize them into three groups receiving intralesional Candida antigen, intralesional bivalent HPV vaccine, or a combination of both. Injections are given into the largest wart every two weeks until complete clearance or for a maximum of five sessions. The protocol is based on the idea that Candida antigen stimulates cell-mediated immunity while the HPV vaccine stimulates humoral immunity, and combining them may improve clearance rates. Primary outcomes include wart clearance and safety/tolerability.
Why it matters
Potential benefit: If successful, this approach could provide a simple in-clinic injection option that clears multiple warts and lowers recurrence without more invasive procedures.
How similar studies have gone: Prior small trials and case series have reported clearance of warts with intralesional Candida antigen, while intralesional use of HPV vaccines is less well established but has some preliminary supportive reports.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * patients with multiple, recalcitrant, or non-recalcitrant common warts of different sites, sizes, duration, and with or without distant lesions will be enrolled in the study Exclusion Criteria: * Pregnant female. Hypersensitivity to Candida antigen or bivalent HPV vaccine
Where it's running
-
Reham Essam
Zagazig, Al Sharqia, Egypt Recruiting
Study contacts
- Principal investigator: Reham Essam, MD — Zagazig University
- Study coordinator: Reham Essam, MD
- Email: rereessam22@gmail.com
- Phone: +201097709477
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
HPV self-sampling in the ED to screen under-screened women
This study tests whether giving an HPV self-sampling kit in the emergency department can help under-screened women get screened for cervical cancer and find those with HPV to guide follow-up care.
-
Cantharidin and occlusion in verruca epithelium: testing a topical treatment for common warts
This Phase 3 study tests VP-102/TO-208 (cantharidin) vs. a vehicle to see if it clears common warts in people 2 years and older who have a normal immune system.
-
Heat combined with a hydrogen peroxide microneedle patch for common warts.
This test will see if applying local heat at 44°C together with a microneedle patch that delivers 3% hydrogen peroxide clears common hand and foot warts in people aged 6 to 65.
-
Long-term follow-up of cantharidin (YCANTH/VP-102/TO-208) treatment for common warts
This follow-up will try applying cantharidin (YCANTH/VP-102/TO-208) every ~21 days for up to four applications to see if it safely clears remaining common warts in people who completed earlier COVE studies.
-
CHW4CervixHealth: HPV self-collection kits with community health workers
This project will test whether giving self-collection HPV kits during community workshops led by community health workers helps increase screening among under-screened women aged 25–65 and will first compare kit results to clinical Pap smears.
-
Preventing cervical cancer with rapid HPV genotyping and same-day self-sampling
This project tests whether a rapid HPV genotyping test on self-collected and provider-collected samples can quickly identify women at high risk so they can receive same-day screening and treatment in low-resource settings.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.